Monster Beverage (MNST) Reports In-Line Q4 EPS

Monster Beverage (NASDAQ: MNST) reported Q4 EPS of $0.47, in-line with the analyst estimate of $0.47. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion.

Rodney C. Sacks, Chairman and Chief Executive Officer, said: “We are pleased to report record gross and net sales for the 2019 fourth quarter and for the 2019 fiscal year, driven by growth in our Monster Energy® brand energy drinks internationally, as well as from sales of our Reign Total Body Fuel™ high performance energy drinks, which we launched in the first quarter of 2019.

“Net sales for the 2019 fourth quarter exceeded $1 billion for the first time, and for the full year exceeded $4 billion for the first time. Net income for the 2019 year exceeded $1 billion, also for the first time.

“During the fourth quarter, we launched Java Monster® Farmer’s Oats and two new Reign Total Body Fuel™ high performance energy drinks in the United States. Internationally, we added various Monster Energy® brand energy drinks, as well as Espresso Monster® to our portfolio in certain countries and launched Monster HydroSport Super Fuel® in Germany, the Republic of Ireland and the United Kingdom during the fourth quarter. Also during the fourth quarter, we launched our Reign Total Body Fuel™ high performance energy drinks in Puerto Rico, the Republic of Ireland and the United Kingdom and are planning further introductions in other international markets in 2020.

“We also launched Predator®, our affordable energy brand in additional international markets during the fourth quarter, with plans for further launches of Predator® this year.

“We have a robust plan for new product introductions in 2020, and most recently launched our Monster Energy® brand energy drinks in Israel, with further country launches and transitions planned for later this year,” Sacks added.

For earnings history and earnings-related data on Monster Beverage (MNST) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial